Serum Biomarkers for Portal Hypertension in Cirrhosis (Pan-CHESS1802)

Serum Biomarkers Associated With Endothelial Dysfunction and Immune Inflammation for Portal Hypertension in Cirrhosis (Pan-CHESS1802)

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03713606

Enrollment

Registered

2018-10-22

Start date

2018-09-30

Completion date

2022-06-01

Last updated

2021-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Portal

Keywords

Portal hypertension, serum biomarker, diagnosis

Brief summary

This is a prospective, multi-center diagnostic trial conducted at 6 liver centers in China designed to study the correlation between serum biomarkers associated with endothelial dysfunction and immune inflammation and hepatic venous pressure gradient in cirrhosis.

Detailed description

Hepatic venous pressure gradient (HVPG) is the gold standard for assessing portal pressure, of which the measurement is invasive and therefore not suitable for routine clinical practice. The detection of serum biomarkers is potential for noninvasive diagnosis of portal hypertension in cirrhosis. However, many are still in the exploratory phases of testing and are not yet ready to enter clinical practice. This study prospectively enrolled participants in 6 liver centers (Beijing YouAn Hospital, Shandong Provincial Hospital, Beijing Shijitan Hospital, Beijing Friendship Hospital, Xingtai People's Hospital, and 302 Hospital of PLA) in China designed to study the correlation between serum biomarkers associated with endothelial dysfunction and immune inflammation and HVPG in cirrhosis.

Interventions

PROCEDUREHVPG measurement

HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* age 18-75 years; * confirmed cirrhosis based on histologic examination of liver or combined physical, laboratory, and radiologic findings, including a nodular surface, a coarse texture, and an enlarged caudate lobe of the liver.

Exclusion criteria

* prior drug therapy (e.g. β-blocker, vasopressin) within two weeks * prior surgeries (e.g. TIPS, partial splenic embolization/ devascularization, splenectomy, liver transplantation) * non-sinusoidal portal hypertension & HCC inability to adhere to study procedures * pregnancy or unknown pregnancy status * no informed consent

Design outcomes

Primary

Measure	Time frame	Description
Correlation between serum biomarkers and HVPG	1 day	Correlation between serum biomarkers and HVPG

Secondary

Measure	Time frame	Description
Correlation between serum biomarkers and HVPG in HBV subgroup	1 day	Correlation between serum biomarkers and HVPG in a subgroup of patients with HBV-related cirrhosis

Countries

China

Contacts

Primary ContactXiaolong Qi, M.D.

qixiaolong@vip.163.com+86 18588602600

Backup ContactYanna Liu

lauyenna@126.com+86 15625076784

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026